NTL-001 / NTL-002 / NTL-003 — Point-of-Wounding Stabilisation

The RAPID Family Without a medic.
Without a cold chain.
Without clinical skill.

Three devices. Five actions. Two minutes. Any soldier.

40% Combat deaths from haemorrhage
887 Potentially survivable — Eastridge 2012
<2 min Full protocol execution time
£250 Estimated per-soldier kit cost
The Protocol Clinical Collaboration

The gap between injury and survival

Haemorrhagic shock kills 90% of potentially survivable combat casualties. The Eastridge et al. 2012 analysis of 4,596 combat deaths across Iraq and Afghanistan identified 887 potentially survivable haemorrhage deaths.


These soldiers did not die because their wounds were unsurvivable. They died because no effective intervention reached them in the minutes immediately after wounding — before a medic arrived, before evacuation began, while they were still bleeding.


Every existing prehospital stabilisation protocol requires a trained medic to administer it. In large-scale combat operations against a peer adversary, that assumption fails. No current protocol converts the casualty themselves — or their immediate buddy — into the primary resuscitation asset. Until now.

"The doctrinal gap is not a shortage of blood products. It is the absence of any intervention that the casualty or an untrained buddy can execute in the first two minutes after wounding — before anyone else arrives." — NTL Programme Documentation

Three devices. Complete protocol.

NTL-001
RAPID
Pen
Dual-chamber auto-injector

Delivers tranexamic acid and sub-anaesthetic ketamine simultaneously via a single intramuscular actuation through clothing. Self-administered to the outer thigh in two seconds. TXA arrests coagulopathy immediately. Ketamine reduces mean arterial pressure 40–45%, cutting the rate of ongoing blood loss before any volume replacement begins.

Administration Self-administered, outer thigh
Time 2 seconds
Payload TXA + Sub-anaesthetic ketamine
Platform BinaJect dual-chamber (ATNAA precedent)
UK Patent Filed March 2026 — 22 Claims
NTL-002
RAPID
Plasma
Dual-compartment frangible-membrane plasma unit

Delivers 500ml of reconstituted freeze-dried plasma. Bend to crack the internal membrane. Shake to mix. Plasma ready in two minutes. No separate sterile water. No syringe. No clinical skill required. The simplest plasma delivery system ever engineered.

Volume 500ml reconstituted plasma
Activation Bend → crack → shake
Reconstitution 2 minutes
Platform Dual-Mix frangible membrane
UK Patent Filed March 2026 — 25 Claims
NTL-003
RAPID
Connect
Pre-primed sterile transfer line

Factory-filled with Water for Injection to BP/EP monograph. No priming required. Dual male Luer lock. Compatible with all standard IO and IV interfaces. Remove caps, connect, open clamp. The transfer line that eliminates the last point of failure in field plasma delivery.

Pre-fill WFI to BP/EP monograph
Connection Dual male Luer lock
Compatibility All standard IO and IV interfaces
Distinction BP/EP WFI priming — no haemolysis risk
UK Patent Filed March 2026 — 22 Claims

Five actions. Any soldier.

No training beyond a single familiarisation session. The casualty themselves — or one untrained buddy — executes the complete protocol.

STAB

Casualty self-administers RAPIDPen to outer thigh through clothing. TXA and ketamine delivered simultaneously. Haemodynamic suppression begins immediately.

2 sec
CRACK & SHAKE

Casualty or buddy activates RAPIDPlasma unit. Bend to crack internal frangible membrane. Shake to reconstitute. 500ml plasma ready in two minutes.

2 min
IO

Buddy applies FAST1 sternal intraosseous device. Single press. Ten seconds. 95% first-attempt success rate in non-specialists. No IV skill required.

10 sec
PLUG & HANG

Buddy connects RAPIDPlasma via RAPIDConnect to IO hub. Remove caps, connect, open clamp. Gravity feeds. The system runs itself. No clinical monitoring required.

30 sec
SECOND STAB

At 30–40 minutes, casualty self-administers second dose. Haemodynamic suppression restored. Buddy contributing their plasma unit simultaneously extends the viable window to 3–4 hours.

30–40 min
Total time — first action to plasma infusing Under 2 minutes

The numbers.

68+ Minutes viable evacuation window under representative haemodynamic modelling — up from 36
3–4 hrs Viable window with buddy plasma pooling — second dose plus additional unit
381 Potentially survivable haemorrhage deaths preventable per equivalent casualty population — conservative modelling against Eastridge baseline
£250 Estimated per-soldier Phase 1 kit cost at military volume procurement — COTS throughout
<£80k Cost per additional life saved — less than 5% of MOD's own £1.8M statistical value of life threshold
£0 Specialist equipment required — every component is commercial off-the-shelf

From battlefield to everywhere.

The same zero-logistics, no-training architecture that makes RAPID deployable in combat makes it deployable wherever haemorrhagic shock occurs before medical help arrives. At £250 per kit, global-scale deployment is economically viable in a way no cold-chain-dependent solution can match.

Mass casualty events
Remote industrial operations
Disaster relief
Wilderness and expedition medicine
Rural pre-hospital emergency

Where we are.

2026
Three patent applications filed — priority dates established
NTL-001 (22 claims), NTL-002 (25 claims), NTL-003 (22 claims). UKDI validation programme submission. TRL 4 → TRL 6.
2027
Field trial programme
TRL 6 → TRL 8. Clinical collaborator engagement. NHS and MOD pre-procurement dialogue.
2028
Procurement pathway
NHS and MOD adoption. NATO allied force expansion. Civilian mass casualty deployment.

Clinical collaborators and procurement partners

We are actively engaging military medical personnel, NHS trauma teams, and procurement partners. If you work in defence medicine, emergency services, or NHS major trauma — we want to hear from you.

Get in touch
Kirk Harper Principal Investigator
kirk_harper@neurosync-technologies.ltd
+44 7944 299117

Neurosync Technologies Ltd
Registered in England · Company No. 16532903

NTL-001 · NTL-002 · NTL-003
UK Patent Applications Filed March 2026